2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 896

Pharmacogenomics Study of Predicting Response of TNF Blocker and Medical Image Progression in Chinese Han Ankylosing Spondylitis Population
Abstract Number: 1050

Pharmacokinetic and pharmacodynamic modelling of the novel anti-ADAMTS-5 nanobody M6495 using the neo-epitope ARGS as a biomarker
Abstract Number: 1728

Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation
Abstract Number: 2338

Pharmacological and Non-Pharmacological Approaches in a Group of Osteoporotic Patients Referring to a Rehabilitation out-Patient Clinic
Abstract Number: 118

Pharmacological Inhibition of JAK/STAT Signaling By Tofacitinib Prevents Experimental Organ Fibrosis: Novel Therapy for Systemic Sclerosis
Abstract Number: 2383

Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry
Abstract Number: 1414

Pharmacovigilance of Biologics for Systemic Juvenile Idiopathic Arthritis Patients By the German Biologics Registry
Abstract Number: 1870

Phase 2 Trial of Induction Therapy with Anti-CD20 (Rituximab) Followed By Maintenance Therapy with Anti-BAFF (Belimumab) in Patients with Active Lupus Nephritis
Abstract Number: 2550

Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar
Abstract Number: 2878

Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
Abstract Number: 1963

Phenome Wide Association Study of IL6R Variant Identifies Drug Target for Cardiovascular Disease and Inflammation
Abstract Number: 1886

Phenotypic Subgroups in IgG4-Related Disease – a Cluster Analysis
Abstract Number: 1076

Phospholipase C-eta2, As a C2 Domain-Containing Protein, Regulate Aggressiveness of Fibroblast‐like Synoviocytes and Ameliorate Arthritis in Experimental Animal Models of Rheumatoid Arthritis
Abstract Number: 1006

Physical Activity at Lower Intensities Reduces Localized IL-1b in a Murine Model of Gout By Systemically Down-Regulating TLR2 Expression on Circulating Neutrophils and Suppressing CXCL1 Expression
Abstract Number: 2918

Physical Activity in Canadian Children with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].